ADC Therapeutics SA, a leader in antibody drug conjugates, has announced the issuance of options to purchase 29,700 common shares to two new employees as part of their inducement plan. This grant is designed to reward employees with a vested interest in the company's success, with shares vesting over four years.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NY63551) on September 02, 2025, and is solely responsible for the information contained therein.